Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (981-990 of 993) with videos related to

Pageof 100
Sort By:
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 26, 2023
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional surveySteven M Yip, Christopher Morash, Michael P Kolinsky, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.
Lancet (London, England)|May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialChris C Parker, Howard Kynaston, Adrian D Cook, et al.
Lancet (London, England)|October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trialChristopher C Parker, Noel W Clarke, Adrian D Cook, et al.
European Urology|June 29, 2017
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017Silke Gillessen, Gerhardt Attard, Tomasz M Beer, et al.
European Urology|February 1, 2020
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019Silke Gillessen, Gerhardt Attard, Tomasz M Beer, et al.
European Urology|April 8, 2022
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al.
European Urology|April 22, 2022
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021Silke Gillessen, Andrew Armstrong, Gert Attard, et al.
Pageof 100

Showing results (981-990 of 993) with videos related to

Sort By:
Pageof 100
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 26, 2023
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional surveySteven M Yip, Christopher Morash, Michael P Kolinsky, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.
Lancet (London, England)|May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialChris C Parker, Howard Kynaston, Adrian D Cook, et al.
Lancet (London, England)|October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trialChristopher C Parker, Noel W Clarke, Adrian D Cook, et al.
European Urology|June 29, 2017
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017Silke Gillessen, Gerhardt Attard, Tomasz M Beer, et al.
European Urology|February 1, 2020
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019Silke Gillessen, Gerhardt Attard, Tomasz M Beer, et al.
European Urology|April 8, 2022
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al.
European Urology|April 22, 2022
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021Silke Gillessen, Andrew Armstrong, Gert Attard, et al.
Pageof 100